Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Denali Therapeutics Inc. (DNLI)
USD22.90
+0.25 (+1.08%)
US NASDAQ Healthcare Biotechnology
Address
161 Oyster Point Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Ryan J. Watts
Website
denalitherapeutics.com
IPO
2017-12-08
CIK 1714899 ISIN US24823R1059
Description
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
News Sentiment (7d)
Based on only 2 articles — low confidence
- DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? Zacks Investment Research
- Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD22.90
+0.25 (+1.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.01
Float Shares
141.68M
Free Float %
89.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.07% | +0.10% | +0.21% | +3.68% | +13.47% | +17.87% | +36.47% | -39.23% | -62.36% | -9.28% | -9.28% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
22.90
Low
23.00
+0.5%
Consensus
33.33
+45.6%
Median
36.00
+57.2%
High
40.00
+74.7%
DCF (Unlevered)
0.92
-96.0%
DCF (Levered)
0.93
-95.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
95% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 17 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
23.00
+0.5%
|
| Last Quarter | 3 |
32.67
+42.7%
|
| Last Year | 8 |
32.63
+42.5%
|
| All Time | 17 |
40.29
+76.0%
|
Quality scores
Altman Z-Score
2.56
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-15.6% Q1'26: +11.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-272.3% Q1'26: +2,550.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.7% Q1'26: +9.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 12 EPS Ana. |
Dec 2027 15 Rev. Ana. 14 EPS Ana. |
Dec 2028 15 Rev. Ana. 14 EPS Ana. |
Dec 2029 11 Rev. Ana. 8 EPS Ana. |
Dec 2030 7 Rev. Ana. 12 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
129.16M
est: 30.35M (+325.6%)
|
26.68M
est: 31.81M (-16.1%)
|
335.66M
est: 92.10M (+264.5%)
|
48.66M
est: 75.99M (-36.0%)
|
108.46M
est: 109.51M (-1.0%)
|
330.53M
est: 1.27M (+25,987.7%)
|
—
est: 11.71M (-100.0%)
|
—
est: 2.50M (-100.0%)
|
38.90M
2.65M – 155.69M
+1,456.0% YoY
|
113.39M
19.68M – 178.05M
+191.5% YoY
|
422.41M
404.34M – 440.48M
+272.5% YoY
|
561.40M
96.44M – 1.26B
+32.9% YoY
|
868.41M
149.18M – 1.95B
+54.7% YoY
|
| EBITDA |
-38.96M
est: -8.09M (-381.7%)
|
-205.19M
est: -178.61M (-14.9%)
|
71.25M
est: -24.54M (+390.4%)
|
-287.16M
est: -173.37M (-65.6%)
|
-330.36M
est: -233.16M (-41.7%)
|
-179.97M
est: -138.0K (-130,338.8%)
|
-492.89M
est: -1.28M (-38,556.7%)
|
-497.63M
est: -272.2K (-182,684.1%)
|
-4.24M
-16.95M – -288.9K
-1,456.0% YoY
|
-12.35M
-19.39M – -2.14M
-191.5% YoY
|
-46.00M
-47.97M – -44.03M
-272.5% YoY
|
-61.14M
-137.33M – -10.50M
-32.9% YoY
|
-94.57M
-212.43M – -16.25M
-54.7% YoY
|
| EBIT |
-46.37M
est: -8.55M (-442.5%)
|
-213.18M
est: -200.81M (-6.2%)
|
62.72M
est: -25.94M (+341.8%)
|
-295.75M
est: -181.47M (-63.0%)
|
-340.74M
est: -248.70M (-37.0%)
|
-196.70M
est: -150.8K (-130,338.7%)
|
-501.88M
est: -1.39M (-35,914.9%)
|
-512.44M
est: -297.6K (-172,119.1%)
|
-4.63M
-18.53M – -315.8K
-1,456.0% YoY
|
-13.50M
-21.19M – -2.34M
-191.5% YoY
|
-50.28M
-52.43M – -48.12M
-272.5% YoY
|
-66.82M
-150.09M – -11.48M
-32.9% YoY
|
-103.36M
-232.17M – -17.76M
-54.7% YoY
|
| Net Income |
-36.24M
est: -219.85M (+83.5%)
|
-197.61M
est: -186.09M (-6.2%)
|
71.14M
est: 41.42B (-99.8%)
|
-290.58M
est: -178.35M (-62.9%)
|
-325.99M
est: -128.38M (-153.9%)
|
-145.22M
est: -419.65M (+65.4%)
|
-422.77M
est: -479.03M (+11.7%)
|
-512.54M
est: -508.02M (-0.9%)
|
-469.79M
-527.64M – -298.37M
+7.5% YoY
|
-487.09M
-519.95M – -369.05M
-3.7% YoY
|
-297.42M
-440.14M – 270.05M
+38.9% YoY
|
-64.02M
-167.74M – 4.91M
+78.5% YoY
|
166.68M
-12.78M – 436.72M
+360.4% YoY
|
| SGA |
32.35M
est: 23.98M (+34.9%)
|
46.48M
est: 25.14M (+84.9%)
|
60.33M
est: 72.78M (-17.1%)
|
79.06M
est: 48.39M (+63.4%)
|
90.48M
est: 74.17M (+22.0%)
|
103.35M
est: 1.21M (+8,448.0%)
|
105.44M
est: 11.17M (+843.7%)
|
97.10M
est: 2.39M (+3,970.1%)
|
37.12M
2.53M – 148.57M
+1,456.0% YoY
|
108.20M
18.78M – 169.91M
+191.5% YoY
|
403.11M
385.86M – 420.35M
+272.5% YoY
|
535.75M
92.03M – 1.20B
+32.9% YoY
|
828.73M
142.36M – 1.86B
+54.7% YoY
|
| EPS |
-0.39
est: -1.34 (+70.8%)
|
-2.07
est: -2.08 (+0.5%)
|
0.65
est: -1.54 (+142.2%)
|
-2.39
est: -2.26 (-5.5%)
|
-2.60
est: -2.62 (+0.8%)
|
-1.06
est: -2.83 (+62.5%)
|
-2.57
est: -2.78 (+7.5%)
|
-2.97
est: -2.95 (-0.5%)
|
-2.56
-3.01 – -1.70
+13.4% YoY
|
-2.48
-2.96 – -2.10
+3.2% YoY
|
-1.04
-2.51 – 1.54
+58.1% YoY
|
-0.36
-0.96 – 0.03
+64.8% YoY
|
0.95
-0.07 – 2.49
+360.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-08 | Wedbush | Outperform | Outperform | Maintain |
| 2026-04-22 | Leerink Partners | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-412.34M
OE per share TTM
-2.33
Owner's Yield
-11.26%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
72.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
110
Total invested
891.57M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARCH Venture Fund VIII, L.P. | 11.07M | 12.30% | — | 11.07M | — | 11.07M | PN | Delaware | 2018-02-02 | ↗ |
| 2 | ARCH Venture Partners VIII, L.P. | 11.07M | 12.30% | — | 11.07M | — | 11.07M | PN | Delaware | 2018-02-02 | ↗ |
| 3 | Clinton Bybee | 11.07M | 12.30% | — | 11.07M | — | 11.07M | IN | Delaware | 2018-02-02 | ↗ |
| 4 | Keith Crandell | 11.07M | 12.30% | — | 11.07M | — | 11.07M | IN | Delaware | 2018-02-02 | ↗ |
| 5 | Robert Nelsen | 11.07M | 12.30% | — | 11.07M | — | 11.07M | IN | Delaware | 2018-02-02 | ↗ |
| 6 | The Vanguard Group - 23-1945930 | 8.16M | 6.68% | — | 170.2K | 7.92M | 246.0K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 7 | Douglas K. Bratton | 7.85M | 6.40% | — | 7.85M | — | 7.85M | IN | — | 2022-02-14 | ↗ |
| 8 | AKDL, L.P. | 7.71M | 6.30% | — | 7.71M | — | 7.71M | PN | — | 2022-02-14 | ↗ |
| 9 | Crestline Investors, Inc. | 7.71M | 6.30% | — | 7.71M | — | 7.71M | CO | — | 2022-02-14 | ↗ |
| 10 | Crestline Management, L.P. | 7.71M | 6.30% | — | 7.71M | — | 7.71M | PN | — | 2022-02-14 | ↗ |
| 11 | Crestline SI (GP), L.P. | 7.71M | 6.30% | — | 7.71M | — | 7.71M | PN | — | 2022-02-14 | ↗ |
| 12 | Wellington Group Holdings LLP | 7.27M | 5.26% | — | 7.03M | — | — | HC | Massachusetts | 2024-02-08 | ↗ |
| 13 | Wellington Investment Advisors Holdings LLP | 7.27M | 5.26% | — | 7.03M | — | — | HC | Massachusetts | 2024-02-08 | ↗ |
| 14 | Wellington Management Group LLP | 7.27M | 5.26% | — | 7.03M | — | — | HC | Massachusetts | 2024-02-08 | ↗ |
| 15 | Abigail P. Johnson | 7.19M | 5.02% | — | — | 7.19M | — | IN | Delaware | 2024-08-16 | ↗ |
| 16 | FMR LLC | 7.19M | 5.02% | 7.19M | — | 7.19M | — | HC | Delaware | 2024-08-16 | ↗ |
| 17 | Wellington Management Company LLP | 7.18M | 5.19% | — | 7.00M | — | — | IA | Massachusetts | 2024-02-08 | ↗ |
| 18 | 5.0%(1)(2) | 6.90M | 5.00% | — | 6.90M | — | 6.90M | HC | Republic of Singapore | 2023-03-30 | ↗ |
| 19 | (1) BlackRock, Inc. | 6.38M | 5.30% | 6.26M | — | 6.38M | — | HC | Delaware | 2021-02-02 | ↗ |
| 20 | Baillie Gifford & Co (Scottish partnership) | 4.92M | 11.00% | — | — | — | — | IA | SCOTLAND UK | 2018-01-31 | ↗ |
| 21 | 52-0556948 | 4.64M | 3.70% | 849.9K | — | 4.64M | — | IA | Maryland | 2022-02-14 | ↗ |
| 22 | Fund V General Partner LLC | 2.73M | 2.20% | — | 2.73M | — | 2.73M | OO | Delaware | 2021-02-16 | ↗ |
| 23 | Fund V, L.P. | 2.73M | 2.20% | — | 2.73M | — | 2.73M | PN | Delaware | 2021-02-16 | ↗ |
| 24 | Ph.D. | 2.73M | 2.20% | — | 2.73M | — | 2.73M | IN | Delaware | 2021-02-16 | ↗ |
| 25 | 95-1411037 | 13.00 | 5.50% | 7.91M | — | 7.91M | — | IA | Delaware | 2024-11-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
110
-143 vs prev Q
New positions
24
Closed positions
162
Increased
61
Reduced
21
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 656.7K +656.7K (+100.0%) | 10.84B +10.8B (+100.0%) | 0.38% +0.381 pp | 1.47% +1.470 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 107.5K +107.5K (+100.0%) | 1.78B +1.8B (+100.0%) | 0.06% +0.062 pp | 0.00% +0.003 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 13.06M +1.1M (+8.9%) | 215.59M +41.4M (+23.8%) | 7.57% +0.578 pp | 0.00% +0.001 pp | USD27.43 -39.8% | 33 qtrs — |
| 4 | BLACKROCK, INC. | 12.72M +425.6K (+3.5%) | 209.93M +31.5M (+17.6%) | 7.37% +0.206 pp | 0.00% +0.000 pp | USD28.36 -41.8% | 6 qtrs — |
| 5 | BAILLIE GIFFORD & CO | 12.31M +719.3K (+6.2%) | 203.25M +34.9M (+20.8%) | 7.14% +0.379 pp | 0.17% +0.044 pp | USD34.53 -52.2% | 33 qtrs — |
| 6 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 7.25M +1.6M (+28.7%) | 119.77M +37.9M (+46.3%) | 4.21% +0.919 pp | 0.08% +0.026 pp | USD14.73 +12.1% | 3 qtrs — |
| 7 | TEMASEK HOLDINGS (PRIVATE) LTD | 7.01M +1.7M (+30.9%) | 115.78M +38.0M (+48.9%) | 4.07% +0.944 pp | 0.37% +0.098 pp | USD21.47 -23.1% | 33 qtrs — |
| 8 | STATE STREET CORP | 6.26M +799.1K (+14.6%) | 103.41M +24.1M (+30.3%) | 3.63% +0.446 pp | 0.00% +0.001 pp | USD24.46 -32.5% | 32 qtrs — |
| 9 | FMR LLC | 6.10M -243.1K (-3.8%) | 100.66M +8.6M (+9.3%) | 3.54% -0.162 pp | 0.01% +0.000 pp | USD28.41 -41.9% | 33 qtrs — |
| 10 | NORGES BANK | 5.12M +5.1M (+100.0%) | 84.52M +84.5M (+100.0%) | 2.97% +2.969 pp | 0.01% +0.009 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 11 | UBS ASSET MANAGEMENT AMERICAS INC | 4.98M -481.3K (-8.8%) | 82.28M +2.9M (+3.7%) | 2.89% -0.297 pp | 0.02% +0.000 pp | USD20.72 -20.3% | 30 qtrs — |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.92M -652.4K (-14.3%) | 64.65M -1.7M (-2.5%) | 2.27% -0.393 pp | 0.01% 0.000 pp | USD23.59 -30.0% | 32 qtrs — |
| 13 | GOLDMAN SACHS GROUP INC | 3.84M +1.7M (+77.3%) | 63.33M +31.9M (+101.6%) | 2.22% +0.963 pp | 0.01% +0.004 pp | USD18.62 -11.3% | 33 qtrs — |
| 14 | BAKER BROS. ADVISORS LP | 3.73M +— (+0.0%) | 61.61M +7.4M (+13.7%) | 2.16% -0.012 pp | 0.36% -0.031 pp | USD23.62 -30.1% | 24 qtrs — |
| 15 | CAPITAL RESEARCH GLOBAL INVESTORS | 3.73M -1.0M (-21.7%) | 61.57M -7.6M (-10.9%) | 2.16% -0.614 pp | 0.01% -0.002 pp | USD24.18 -31.7% | 14 qtrs — |
| 16 | ALLIANCEBERNSTEIN L.P. | 3.56M +37.5K (+1.1%) | 58.74M +7.6M (+14.9%) | 2.06% +0.010 pp | 0.02% +0.003 pp | USD23.66 -30.2% | 31 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 3.46M -7.9K (-0.2%) | 57.10M +6.8M (+13.4%) | 2.01% -0.016 pp | 0.00% +0.000 pp | USD28.75 -42.6% | 32 qtrs — |
| 18 | HOLOCENE ADVISORS, LP | 3.15M +17.0K (+0.5%) | 52.05M +6.5M (+14.3%) | 1.83% 0.000 pp | 0.11% +0.006 pp | USD14.46 +14.2% | 8 qtrs — |
| 19 | CRESTLINE MANAGEMENT, LP | 2.81M -600.0K (-17.6%) | 46.41M -3.1M (-6.3%) | 1.63% -0.359 pp | 87.02% +1.766 pp | USD41.05 -59.8% | 33 qtrs — |
| 20 | FISHER ASSET MANAGEMENT, LLC | 2.59M +957.9K (+58.7%) | 42.75M +19.1M (+80.5%) | 1.50% +0.550 pp | 0.01% +0.006 pp | USD17.09 -3.4% | 9 qtrs — |
| 21 | UBS GROUP AG | 2.40M +392.4K (+19.5%) | 39.70M +10.5M (+35.9%) | 1.39% +0.221 pp | 0.01% +0.002 pp | USD16.93 -2.5% | 33 qtrs — |
| 22 | DIMENSIONAL FUND ADVISORS LP | 2.37M +17.1K (+0.7%) | 39.20M +5.0M (+14.5%) | 1.38% +0.002 pp | 0.01% +0.001 pp | USD23.47 -29.7% | 27 qtrs — |
| 23 | ABRDN PLC | 2.03M +919.4K (+82.6%) | 33.56M +17.4M (+107.6%) | 1.18% +0.530 pp | 0.05% +0.026 pp | USD16.53 -0.1% | 9 qtrs — |
| 24 | CASDIN CAPITAL, LLC | 1.84M +950.0K (+106.7%) | 30.38M +17.5M (+135.1%) | 1.07% +0.548 pp | 1.89% +0.809 pp | USD21.53 -23.3% | 29 qtrs — |
| 25 | LYNX1 CAPITAL MANAGEMENT LP | 1.74M +1.5M (+564.4%) | 28.71M +24.9M (+655.5%) | 1.01% +0.856 pp | 5.81% +5.038 pp | USD16.21 +1.9% | 2 qtrs — |
| 26 | POINT72 ASSET MANAGEMENT, L.P. | 1.70M -819.5K (-32.5%) | 28.07M -8.5M (-23.3%) | 0.99% -0.484 pp | 0.03% -0.030 pp | USD14.05 +17.5% | 14 qtrs — |
| 27 | PRINCIPAL FINANCIAL GROUP INC | 1.52M +252.9K (+19.9%) | 25.16M +6.7M (+36.3%) | 0.88% +0.143 pp | 0.01% +0.004 pp | USD24.14 -31.6% | 33 qtrs — |
| 28 | SIREN, L.L.C. | 1.40M +575.0K (+70.0%) | 23.06M +11.1M (+93.3%) | 0.81% +0.331 pp | 0.69% +0.221 pp | USD23.93 -31.0% | 6 qtrs — |
| 29 | PICTET ASSET MANAGEMENT HOLDING SA | 1.33M +829.9K (+166.3%) | 21.98M +14.7M (+203.3%) | 0.77% +0.480 pp | 0.02% +0.014 pp | USD15.62 +5.7% | 10 qtrs — |
| 30 | MORGAN STANLEY | 1.22M -469.6K (-27.8%) | 20.14M -4.4M (-17.9%) | 0.71% -0.278 pp | 0.00% 0.000 pp | USD24.71 -33.2% | 33 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.20M +49.1K (+4.3%) | 19.82M +3.1M (+18.6%) | 0.70% +0.025 pp | 0.00% +0.000 pp | USD28.39 -41.8% | 32 qtrs — |
| 32 | NORTHERN TRUST CORP | 1.20M -34.4K (-2.8%) | 19.81M +1.9M (+10.5%) | 0.70% -0.024 pp | 0.00% +0.000 pp | USD30.08 -45.1% | 32 qtrs — |
| 33 | CANDRIAM S.C.A. | 1.17M +332.8K (+39.9%) | 19.26M +7.2M (+59.1%) | 0.68% +0.190 pp | 0.10% +0.033 pp | USD26.46 -37.6% | 19 qtrs — |
| 34 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 1.02M +1.0M (+100.0%) | 16.89M +16.9M (+100.0%) | 0.59% +0.594 pp | 0.13% +0.133 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 35 | MASTERS CAPITAL MANAGEMENT LLC | 1.00M +250.0K (+33.3%) | 16.51M +5.6M (+51.6%) | 0.58% +0.143 pp | 0.67% +0.279 pp | USD14.70 +12.3% | 3 qtrs — |
| 36 | FORESITE CAPITAL MANAGEMENT VI LLC | 1.00M +— (+0.0%) | 16.51M +2.0M (+13.7%) | 0.58% -0.003 pp | 4.99% -0.619 pp | USD14.52 +13.7% | 2 qtrs — |
| 37 | BANK OF AMERICA CORP /DE/ | 932.1K -29.0K (-3.0%) | 15.39M +1.4M (+10.3%) | 0.54% -0.020 pp | 0.00% +0.000 pp | USD16.95 -2.6% | 33 qtrs — |
| 38 | ALYESKA INVESTMENT GROUP, L.P. | 859.1K +859.1K (+100.0%) | 14.18M +14.2M (+100.0%) | 0.50% +0.498 pp | 0.04% +0.040 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 39 | CITADEL ADVISORS LLC | 779.1K +90.9K (+13.2%) | 12.86M +2.9M (+28.7%) | 0.45% +0.051 pp | 0.00% +0.000 pp | USD18.11 -8.8% | 28 qtrs — |
| 40 | MARSHALL WACE, LLP | 763.9K -23.1K (-2.9%) | 12.61M +1.2M (+10.4%) | 0.44% -0.016 pp | 0.01% 0.000 pp | USD19.93 -17.2% | 9 qtrs — |
| 41 | BANK OF NEW YORK MELLON CORP | 762.1K -38.7K (-4.8%) | 12.58M +955.2K (+8.2%) | 0.44% -0.025 pp | 0.00% +0.000 pp | USD35.72 -53.8% | 32 qtrs — |
| 42 | PALO ALTO INVESTORS LP | 641.2K +233.2K (+57.2%) | 10.59M +4.7M (+78.7%) | 0.37% +0.134 pp | 1.47% +0.378 pp | USD15.05 +9.7% | 3 qtrs — |
| 43 | CERCANO MANAGEMENT LLC | 625.0K +— (+0.0%) | 10.32M +1.2M (+13.7%) | 0.36% -0.002 pp | 0.39% +0.043 pp | USD27.81 -40.6% | 13 qtrs — |
| 44 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 591.5K -344.8K (-36.8%) | 9.77M -3.8M (-28.2%) | 0.34% -0.203 pp | 0.03% -0.011 pp | USD13.96 +18.3% | 4 qtrs — |
| 45 | QUBE RESEARCH & TECHNOLOGIES LTD | 590.3K +362.3K (+158.9%) | 9.75M +6.4M (+194.4%) | 0.34% +0.209 pp | 0.01% +0.007 pp | USD15.74 +4.9% | 5 qtrs — |
| 46 | SEGALL BRYANT & HAMILL, LLC | 537.0K +24.0K (+4.7%) | 8.87M +1.4M (+19.0%) | 0.31% +0.012 pp | 0.12% +0.021 pp | USD17.46 -5.4% | 5 qtrs — |
| 47 | ENSIGN PEAK ADVISORS, INC | 515.7K -18.4K (-3.4%) | 8.51M +759.8K (+9.8%) | 0.30% -0.012 pp | 0.02% +0.002 pp | USD20.11 -17.9% | 25 qtrs — |
| 48 | VESTAL POINT CAPITAL, LP | 465.0K +465.0K (+100.0%) | 7.68M +7.7M (+100.0%) | 0.27% +0.270 pp | 0.26% +0.261 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 49 | HUDSON BAY CAPITAL MANAGEMENT LP | 450.0K +145.0K (+47.5%) | 7.43M +3.0M (+67.8%) | 0.26% +0.083 pp | 0.02% +0.010 pp | USD16.07 +2.7% | 9 qtrs — |
| 50 | SCHRODER INVESTMENT MANAGEMENT GROUP | 451.0K +241.4K (+115.2%) | 7.40M +4.4M (+143.2%) | 0.26% +0.139 pp | 0.01% +0.003 pp | USD17.47 -5.5% | 9 qtrs — |
| 51 | TWO SIGMA INVESTMENTS, LP | 430.2K +163.9K (+61.5%) | 7.10M +3.2M (+83.7%) | 0.25% +0.094 pp | 0.01% +0.004 pp | USD15.56 +6.1% | 23 qtrs — |
| 52 | STEMPOINT CAPITAL LP | 419.1K -1.3M (-75.8%) | 6.92M -18.3M (-72.5%) | 0.24% -0.769 pp | 1.19% -3.860 pp | USD16.83 -1.9% | 7 qtrs — |
| 53 | BARCLAYS PLC | 407.4K +151.5K (+59.2%) | 6.73M -728.4K (-9.8%) | 0.24% +0.087 pp | 0.00% 0.000 pp | USD19.44 -15.1% | 32 qtrs — |
| 54 | AMERICAN CENTURY COMPANIES INC | 379.1K +21.7K (+6.1%) | 6.26M +1.1M (+20.6%) | 0.22% +0.011 pp | 0.00% +0.001 pp | USD28.65 -42.4% | 28 qtrs — |
| 55 | MILLENNIUM MANAGEMENT LLC | 369.8K -937.4K (-71.7%) | 6.10M -12.9M (-67.8%) | 0.21% -0.548 pp | 0.00% -0.006 pp | USD15.17 +8.8% | 23 qtrs — |
| 56 | CLARIUS GROUP, LLC | 369.0K +9.3K (+2.6%) | 6.09M +868.6K (+16.6%) | 0.21% +0.004 pp | 0.35% +0.039 pp | USD30.16 -45.3% | 19 qtrs — |
| 57 | TD ASSET MANAGEMENT INC | 339.4K -55.2K (-14.0%) | 5.60M -125.9K (-2.2%) | 0.20% -0.033 pp | 0.00% 0.000 pp | USD21.01 -21.4% | 32 qtrs — |
| 58 | DAFNA CAPITAL MANAGEMENT LLC | 318.5K +150.0K (+89.0%) | 5.26M +2.8M (+114.9%) | 0.18% +0.086 pp | 1.22% +0.617 pp | USD15.02 +9.9% | 4 qtrs — |
| 59 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 298.8K +297.5K (+23,408.4%) | 4.93M +4.9M (+27,305.6%) | 0.17% +0.173 pp | 0.01% +0.006 pp | USD16.50 +0.1% | 3 qtrs — |
| 60 | INVESCO LTD. | 291.9K +42.5K (+17.0%) | 4.82M +1.2M (+33.1%) | 0.17% +0.024 pp | 0.00% +0.000 pp | USD23.32 -29.2% | 30 qtrs — |
| 61 | MAREX GROUP PLC | 287.0K -4.0K (-1.4%) | 4.74M +513.1K (+12.1%) | 0.17% -0.003 pp | 0.03% +0.000 pp | USD14.04 +17.6% | 3 qtrs — |
| 62 | NUVEEN, LLC | 275.5K -9.3K (-3.3%) | 4.55M +413.7K (+10.0%) | 0.16% -0.006 pp | 0.00% +0.000 pp | USD13.78 +19.8% | 4 qtrs — |
| 63 | SWISS NATIONAL BANK | 273.8K +6.3K (+2.4%) | 4.52M +636.3K (+16.4%) | 0.16% +0.003 pp | 0.00% +0.000 pp | USD23.79 -30.6% | 31 qtrs — |
| 64 | EDMOND DE ROTHSCHILD HOLDING S.A. | 225.7K +20.0K (+9.7%) | 3.73M +739.5K (+24.8%) | 0.13% +0.011 pp | 0.05% +0.007 pp | USD39.64 -58.4% | 21 qtrs — |
| 65 | TREXQUANT INVESTMENT LP | 209.6K -221.0K (-51.3%) | 3.46M -2.8M (-44.6%) | 0.12% -0.130 pp | 0.03% -0.034 pp | USD15.69 +5.2% | 6 qtrs — |
| 66 | BURKEHILL GLOBAL MANAGEMENT, LP | 200.0K +200.0K (+100.0%) | 3.30M +3.3M (+100.0%) | 0.12% +0.116 pp | 0.22% +0.218 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 67 | SCS CAPITAL MANAGEMENT LLC | 198.0K +— (+0.0%) | 3.27M +394.0K (+13.7%) | 0.11% -0.001 pp | 0.03% +0.003 pp | USD13.60 +21.4% | 4 qtrs — |
| 68 | WELLS FARGO & COMPANY/MN | 193.7K +89.5K (+85.9%) | 3.20M +1.7M (+111.4%) | 0.11% +0.052 pp | 0.00% +0.000 pp | USD22.44 -26.4% | 33 qtrs — |
| 69 | RAFFERTY ASSET MANAGEMENT, LLC | 191.6K +8.7K (+4.7%) | 3.16M +507.3K (+19.1%) | 0.11% +0.004 pp | 0.01% +0.002 pp | USD22.39 -26.3% | 28 qtrs — |
| 70 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 184.2K -21.6K (-10.5%) | 3.03M +41.0K (+1.4%) | 0.11% -0.013 pp | 0.00% +0.000 pp | USD23.74 -30.5% | 32 qtrs — |
| 71 | RHUMBLINE ADVISERS | 183.0K -18.6K (-9.2%) | 3.02M +94.6K (+3.2%) | 0.11% -0.011 pp | 0.00% +0.000 pp | USD29.32 -43.7% | 32 qtrs — |
| 72 | AMERIPRISE FINANCIAL INC | 180.2K +80.7K (+81.0%) | 2.98M +1.5M (+105.8%) | 0.10% +0.047 pp | 0.00% +0.000 pp | USD15.12 +9.2% | 6 qtrs — |
| 73 | JPMORGAN CHASE & CO | 171.9K -3.1K (-1.8%) | 2.84M +297.6K (+11.7%) | 0.10% -0.002 pp | 0.00% +0.000 pp | USD27.35 -39.6% | 32 qtrs — |
| 74 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 167.7K +167.7K (+100.0%) | 2.77M +2.8M (+100.0%) | 0.10% +0.097 pp | 0.04% +0.043 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 75 | TWO SIGMA ADVISERS, LP | 154.8K +64.8K (+72.0%) | 2.56M +1.2M (+95.6%) | 0.09% +0.037 pp | 0.01% +0.002 pp | USD15.71 +5.1% | 5 qtrs — |
| 76 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | 153.8K -17.8K (-10.4%) | 2.54M +48.0K (+1.9%) | 0.09% -0.011 pp | 0.02% +0.000 pp | USD29.79 -44.6% | 14 qtrs — |
| 77 | GROUPAMA ASSET MANAGMENT | 151.6K +15.8K (+11.7%) | 2.50M +531.6K (+27.0%) | 0.09% +0.009 pp | 0.04% +0.008 pp | USD18.47 -10.6% | 9 qtrs — |
| 78 | SG AMERICAS SECURITIES, LLC | 149.6K +111.4K (+291.6%) | 2.47M +1.9M (+345.0%) | 0.09% +0.065 pp | 0.00% +0.001 pp | USD16.00 +3.2% | 28 qtrs — |
| 79 | LEGAL & GENERAL GROUP PLC | 131.2K -12.7K (-8.8%) | 2.17M +76.3K (+3.7%) | 0.08% -0.008 pp | 0.00% +0.000 pp | USD34.23 -51.8% | 33 qtrs — |
| 80 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 129.4K -117.0 (-0.1%) | 2.14M +255.8K (+13.6%) | 0.08% -0.001 pp | 0.00% +0.000 pp | USD31.32 -47.3% | 32 qtrs — |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 128.8K -1.1K (-0.8%) | 2.13M +239.4K (+12.7%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD19.37 -14.8% | 7 qtrs — |
| 82 | ALGERT GLOBAL LLC | 127.0K +25.8K (+25.4%) | 2.10M +627.0K (+42.7%) | 0.07% +0.015 pp | 0.03% +0.008 pp | USD14.57 +13.3% | 8 qtrs — |
| 83 | ALPS ADVISORS INC | 120.7K +50.5K (+71.9%) | 1.99M +973.3K (+95.4%) | 0.07% +0.029 pp | 0.01% +0.006 pp | USD22.89 -27.9% | 15 qtrs — |
| 84 | WOODLINE PARTNERS LP | 114.1K +565.0 (+0.5%) | 1.88M +235.2K (+14.3%) | 0.07% +0.000 pp | 0.01% -0.001 pp | USD19.56 -15.6% | 17 qtrs — |
| 85 | B. METZLER SEEL. SOHN & CO. AG | 112.3K +112.3K (+100.0%) | 1.84M +1.8M (+100.0%) | 0.07% +0.065 pp | 0.02% +0.016 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 86 | D.A. DAVIDSON & CO. | 106.9K +106.9K (+100.0%) | 1.77M +1.8M (+100.0%) | 0.06% +0.062 pp | 0.01% +0.011 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 87 | DEUTSCHE BANK AG\ | 105.1K -102.5K (-49.4%) | 1.73M -1.3M (-42.4%) | 0.06% -0.060 pp | 0.00% 0.000 pp | USD25.81 -36.0% | 32 qtrs — |
| 88 | GHISALLO CAPITAL MANAGEMENT LLC | 100.0K +100.0K (+100.0%) | 1.65M +1.7M (+100.0%) | 0.06% +0.058 pp | 0.07% +0.074 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 89 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 100.0K +— (+0.0%) | 1.65M +199.0K (+13.7%) | 0.06% 0.000 pp | 0.15% -0.006 pp | USD13.60 +21.4% | 4 qtrs — |
| 90 | INTEGRATED WEALTH CONCEPTS LLC | 94.6K +3.5K (+3.9%) | 1.56M +239.2K (+18.1%) | 0.05% +0.002 pp | 0.02% +0.007 pp | USD14.08 +17.3% | 3 qtrs — |
| 91 | Y-INTERCEPT (HONG KONG) LTD | 93.6K +93.6K (+100.0%) | 1.55M +1.5M (+100.0%) | 0.05% +0.054 pp | 0.03% +0.035 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 92 | MONASHEE INVESTMENT MANAGEMENT LLC | 91.6K +91.6K (+100.0%) | 1.51M +1.5M (+100.0%) | 0.05% +0.053 pp | 0.85% +0.852 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 93 | HRT FINANCIAL LP | 78.4K +78.4K (+100.0%) | 1.29M +1.3M (+100.0%) | 0.05% +0.045 pp | 0.00% +0.004 pp | USD16.51 +0.0% | 1 qtrs NEW |
| 94 | METLIFE INVESTMENT MANAGEMENT, LLC | 75.2K -3.9K (-4.9%) | 1.24M +92.8K (+8.1%) | 0.04% -0.003 pp | 0.01% +0.001 pp | USD30.09 -45.1% | 32 qtrs — |
| 95 | STATE OF WISCONSIN INVESTMENT BOARD | 73.6K -6.5K (-8.2%) | 1.21M +51.4K (+4.4%) | 0.04% -0.004 pp | 0.00% +0.000 pp | USD34.73 -52.5% | 30 qtrs — |
| 96 | PROFUND ADVISORS LLC | 71.6K +31.5K (+78.4%) | 1.18M +599.6K (+102.8%) | 0.04% +0.018 pp | 0.04% +0.017 pp | USD19.77 -16.5% | 19 qtrs — |
| 97 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 70.8K +44.6K (+170.1%) | 1.17M +788.6K (+207.1%) | 0.04% +0.026 pp | 0.00% +0.001 pp | USD15.51 +6.4% | 4 qtrs — |
| 98 | PIER 88 INVESTMENT PARTNERS LLC | 68.2K +760.0 (+1.1%) | 1.13M +146.8K (+15.0%) | 0.04% +0.000 pp | 0.25% +0.068 pp | USD21.35 -22.7% | 30 qtrs — |
| 99 | 1492 CAPITAL MANAGEMENT LLC | 67.5K +67.5K (+100.0%) | 1.11M +1.1M (+100.0%) | 0.04% +0.039 pp | 0.43% +0.427 pp | USD16.51 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 114 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 2.08% | 4.43M | 0.50% |
| 2 | Virtus Biotech ETF BBP | 1.53% | 1.50M | 0.34% |
| 3 | Invesco Dorsey Wright Healthcare Momentum ETF PTH | 1.05% | 1.78M | 0.72% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.83% | 297.1K | 0.45% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 0.83% | 89.49M | 0.35% |
| 6 | Research Affiliates Deletions ETF NIXT | 0.63% | 217.8K | 0.09% |
| 7 | American Century Focused Dynamic Growth ETF FDG | 0.38% | 1.59M | 0.45% |
| 8 | iShares Biotechnology ETF IBB | 0.29% | 27.58M | 0.44% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.28% | 1.30M | 0.40% |
| 10 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.28% | 209.3K | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
3.00
Bullish
Buys
4
Sells
2
Shares acquired
546.6K
Shares disposed
52.4K
Cash buys
—
Cash sales
2.00
Net activity
+494,224
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Chin Peter Scott | Officer | — | — | Common Stock | 0 | 0.00 | — | 204,402 | D | ↗ |
| 2026-01-06 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 35,198 | 16.50 | 580.8K | 296,833 | D | ↗ |
| 2026-01-06 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 17,218 | 16.50 | 284.1K | 282,828 | D | ↗ |
| 2026-01-03 | Watts Ryan J. | Director / Officer | A-Award | A | Common Stock | 78,960 | 0.00 | — | 332,031 | D | ↗ |
| 2026-01-03 | Schuth Alexander O. | Officer | A-Award | A | Stock Option (right to buy) | 173,100 | 16.27 | 2.82M | 173,100 | D | ↗ |
| 2025-12-11 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | $0.01 Prefunded Warrants | 2,095,191 | 0.01 | 21.0K | 25,996,310 | I | ↗ |
| 2025-11-04 | Van Hauwermeiren Timothy | Director | A-Award | A | Stock Option (right to buy) | 31,897 | 14.92 | 475.9K | 31,897 | D | ↗ |
| 2025-09-03 | Watts Ryan J. | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 2,152,604 | I | ↗ |
| 2025-08-13 | Ho Carole | Officer | S-Sale | D | Common Stock | 806 | 14.64 | 11.8K | 216,585 | D | ↗ |
| 2025-08-12 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,937 | 13.58 | 39.9K | 242,346 | D | ↗ |
| 2025-08-12 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,937 | 13.58 | 39.9K | 217,391 | D | ↗ |
| 2025-08-05 | Ho Carole | Officer | M-Exempt | A | Common Stock | 44,655 | 0.68 | 30.4K | 220,328 | D | ↗ |
| 2025-07-09 | Watts Ryan J. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 455,282 | 0.68 | 309.6K | 622,809 | D | ↗ |
| 2025-06-03 | Thornberry Nancy | Director | A-Award | A | Stock Option (right to buy) | 18,111 | 13.93 | 252.3K | 18,111 | D | ↗ |
| 2025-06-03 | Tessier-Lavigne Marc | Director | A-Award | A | Stock Option (right to buy) | 18,111 | 13.93 | 252.3K | 18,111 | D | ↗ |
| 2025-06-03 | Schenkein David P | Director | A-Award | A | Common Stock | 6,037 | 0.00 | — | 15,257 | D | ↗ |
| 2025-06-03 | Krognes Steve E. | Director | A-Award | A | Stock Option (right to buy) | 18,111 | 13.93 | 252.3K | 18,111 | D | ↗ |
| 2025-06-03 | Klein Peter S | Director | A-Award | A | Stock Option (right to buy) | 18,111 | 13.93 | 252.3K | 18,111 | D | ↗ |
| 2025-06-03 | FLATLEY JAY T | Director | A-Award | A | Stock Option (right to buy) | 18,111 | 13.93 | 252.3K | 18,111 | D | ↗ |
| 2025-06-03 | Cook Jennifer E. | Director | A-Award | A | Stock Option (right to buy) | 18,111 | 13.93 | 252.3K | 18,111 | D | ↗ |
| 2025-06-03 | BAKER JULIAN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-03 | BAKER BROS. ADVISORS LP | Director | — | — | Common Stock | 0 | 0.00 | — | 3,405,393 | I | ↗ |
| 2025-01-07 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 7,650 | 20.81 | 159.2K | 253,071 | D | ↗ |
| 2025-01-07 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,907 | 20.81 | 60.5K | 244,308 | D | ↗ |
| 2025-01-07 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 3,339 | 20.81 | 69.5K | 25,757 | D | ↗ |
| 2025-01-07 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,907 | 20.81 | 60.5K | 175,673 | D | ↗ |
| 2025-01-06 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 29,266 | 20.22 | 591.8K | 260,721 | D | ↗ |
| 2025-01-06 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 12,255 | 20.22 | 247.8K | 247,215 | D | ↗ |
| 2025-01-06 | Ho Carole | Officer | S-Sale | D | Common Stock | 12,255 | 20.22 | 247.8K | 178,580 | D | ↗ |
| 2025-01-03 | Watts Ryan J. | Director / Officer | A-Award | A | Stock Option (right to buy) | 162,540 | 21.26 | 3.46M | 162,540 | D | ↗ |
| 2025-01-03 | Schuth Alexander O. | Officer | A-Award | A | Common Stock | 54,180 | 0.00 | — | 259,470 | D | ↗ |
| 2025-01-03 | Ho Carole | Officer | A-Award | A | Stock Option (right to buy) | 162,540 | 21.26 | 3.46M | 162,540 | D | ↗ |
| 2025-01-02 | SATO VICKI L | Director | S-Sale | D | Common Stock | 3,080 | 20.91 | 64.4K | 107,976 | D | ↗ |
| 2024-12-31 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 30,000 | 20.25 | 607.5K | 29,096 | D | ↗ |
| 2024-12-27 | Schuth Alexander O. | Officer | M-Exempt | A | Common Stock | 6,708 | 5.28 | 35.4K | 205,290 | D | ↗ |
| 2024-11-25 | Ho Carole | Officer | M-Exempt | A | Common Stock | 17,845 | 0.68 | 12.1K | 136,655 | D | ↗ |
| 2024-11-22 | Schuth Alexander O. | Officer | M-Exempt | A | Common Stock | 20,516 | 0.68 | 14.0K | 198,582 | D | ↗ |
| 2024-11-11 | Schenkein David P | Director | M-Exempt | A | Common Stock | 47,165 | 18.00 | 849.0K | 68,661 | D | ↗ |
| 2024-11-07 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 300 | 31.29 | 9.4K | 178,066 | D | ↗ |
| 2024-11-07 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,020 | 30.00 | 30.6K | 111,056 | D | ↗ |
| 2024-11-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 3,080 | 27.07 | 83.4K | 112,076 | D | ↗ |
| 2024-10-18 | Watts Ryan J. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 40,000 | 0.68 | 27.2K | 1,078,091 | D | ↗ |
| 2024-09-30 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 30,000 | 29.03 | 870.9K | 29,096 | D | ↗ |
| 2024-09-13 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,020 | 30.00 | 30.6K | 115,156 | — | ↗ |
| 2024-09-03 | SATO VICKI L | Director | S-Sale | D | Common Stock | 2,980 | 24.99 | 74.5K | 116,276 | — | ↗ |
| 2024-08-21 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,547 | 24.78 | 63.1K | 178,066 | — | ↗ |
| 2024-08-21 | Ho Carole | Officer | S-Sale | D | Common Stock | 14,098 | 24.41 | 344.1K | 124,717 | — | ↗ |
| 2024-08-20 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 2,260 | 23.79 | 53.8K | 235,807 | — | ↗ |
| 2024-08-20 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 3,353 | 23.54 | 78.9K | 180,613 | — | ↗ |
| 2024-08-20 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 1,727 | 23.79 | 41.1K | 32,677 | — | ↗ |
| 2024-08-20 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,453 | 23.79 | 58.4K | 138,815 | — | ↗ |
| 2024-08-13 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,272 | 22.89 | 52.0K | 186,419 | — | ↗ |
| 2024-08-13 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,337 | 22.89 | 53.5K | 141,268 | — | ↗ |
| 2024-07-01 | SATO VICKI L | Director | S-Sale | D | Common Stock | 100 | 22.86 | 2.3K | 119,256 | — | ↗ |
| 2024-07-01 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 29,900 | 22.12 | 661.4K | 34,504 | — | ↗ |
| 2024-06-13 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 688 | 21.79 | 15.0K | 52,620 | — | ↗ |
| 2024-06-06 | Cook Jennifer E. | Director | S-Sale | D | Common Stock | 1,458 | 21.73 | 31.7K | 20,038 | — | ↗ |
| 2024-05-31 | Thornberry Nancy | Director | A-Award | A | Stock Option (right to buy) | 17,901 | 18.56 | 332.2K | 17,901 | — | ↗ |
| 2024-05-31 | Tessier-Lavigne Marc | Director | A-Award | A | Common Stock | 5,967 | 0.00 | — | 1,880,539 | — | ↗ |
| 2024-05-31 | Schenkein David P | Director | A-Award | A | Stock Option (right to buy) | 17,901 | 18.56 | 332.2K | 17,901 | — | ↗ |
| 2024-05-31 | SATO VICKI L | Director | A-Award | A | Stock Option (right to buy) | 17,901 | 18.56 | 332.2K | 17,901 | — | ↗ |
| 2024-05-31 | Krognes Steve E. | Director | A-Award | A | Stock Option (right to buy) | 17,901 | 18.56 | 332.2K | 17,901 | — | ↗ |
| 2024-05-31 | Klein Peter S | Director | A-Award | A | Common Stock | 5,967 | 0.00 | — | 21,496 | — | ↗ |
| 2024-05-31 | Harris Erik | Director | A-Award | A | Stock Option (right to buy) | 17,901 | 18.56 | 332.2K | 17,901 | — | ↗ |
| 2024-05-31 | FLATLEY JAY T | Director | A-Award | A | Common Stock | 5,967 | 0.00 | — | 10,183 | — | ↗ |
| 2024-05-31 | Cook Jennifer E. | Director | A-Award | A | Stock Option (right to buy) | 17,901 | 18.56 | 332.2K | 17,901 | — | ↗ |
| 2024-05-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,674 | 20.39 | 34.1K | 116,369 | — | ↗ |
| 2024-04-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 18.29 | 30.5K | 118,043 | — | ↗ |
| 2024-04-01 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 92,500 | 20.50 | 1.90M | 47,341 | — | ↗ |
| 2024-03-29 | Watts Ryan J. | Director / Officer | G-Gift | D | Common Stock | 40,000 | 0.00 | — | 2,202,604 | — | ↗ |
| 2024-03-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 20.10 | 33.5K | 119,709 | — | ↗ |
| 2024-02-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 18.37 | 30.6K | 121,375 | — | ↗ |
| 2024-02-14 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 20,128 | 17.66 | 355.5K | 187,341 | — | ↗ |
| 2024-02-14 | Ho Carole | Officer | S-Sale | D | Common Stock | 1,405 | 17.79 | 25.0K | 143,605 | — | ↗ |
| 2024-02-13 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 9,589 | 17.29 | 165.8K | 238,067 | — | ↗ |
| 2024-02-13 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,716 | 17.29 | 47.0K | 207,469 | — | ↗ |
| 2024-02-13 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 2,750 | 17.29 | 47.5K | 139,841 | — | ↗ |
| 2024-02-13 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,784 | 17.29 | 48.1K | 145,010 | — | ↗ |
| 2024-02-08 | Schuth Alexander O. | Officer | M-Exempt | A | Common Stock | 50,000 | 0.68 | 34.0K | 210,185 | — | ↗ |
| 2024-01-16 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 18.42 | 30.7K | 123,041 | — | ↗ |
| 2024-01-10 | Ho Carole | Officer | S-Sale | D | Common Stock | 4,668 | 19.02 | 88.8K | 147,794 | — | ↗ |
| 2024-01-09 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 7,818 | 19.78 | 154.6K | 2,268,363 | — | ↗ |
| 2024-01-05 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 17,483 | 19.43 | 339.7K | 2,276,181 | — | ↗ |
| 2024-01-05 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 9,972 | 19.43 | 193.8K | 539,307 | — | ↗ |
| 2024-01-05 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 3,208 | 19.43 | 62.3K | 142,591 | — | ↗ |
| 2024-01-05 | Ho Carole | Officer | S-Sale | D | Common Stock | 9,972 | 19.43 | 193.8K | 198,777 | — | ↗ |
| 2024-01-03 | Watts Ryan J. | Director / Officer | A-Award | A | Common Stock | 89,520 | 0.00 | — | 272,957 | — | ↗ |
| 2024-01-03 | Schuth Alexander O. | Officer | A-Award | A | Common Stock | 53,720 | 0.00 | — | 170,157 | — | ↗ |
| 2024-01-03 | Ho Carole | Officer | A-Award | A | Common Stock | 53,720 | 0.00 | — | 162,434 | — | ↗ |
| 2023-12-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 23.39 | 39.0K | 124,707 | — | ↗ |
| 2023-11-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 19.13 | 31.9K | 126,373 | — | ↗ |
| 2023-10-16 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 20.66 | 34.4K | 128,039 | — | ↗ |
| 2023-09-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,626 | 23.60 | 38.4K | 129,745 | — | ↗ |
| 2023-08-23 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,522 | 23.17 | 58.4K | 518,989 | — | ↗ |
| 2023-08-23 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,522 | 23.22 | 58.6K | 182,809 | — | ↗ |
| 2023-08-21 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 2,309 | 22.59 | 52.2K | 2,242,604 | — | ↗ |
| 2023-08-21 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,478 | 22.59 | 56.0K | 521,511 | — | ↗ |
| 2023-08-21 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 1,419 | 22.60 | 32.1K | 145,799 | — | ↗ |
| 2023-08-21 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,478 | 22.60 | 56.0K | 185,331 | — | ↗ |
| 2023-08-15 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 24.30 | 40.5K | 131,371 | — | ↗ |
| 2023-08-14 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,772 | 23.67 | 65.6K | 518,989 | — | ↗ |
| 2023-08-14 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,768 | 23.79 | 65.9K | 182,809 | — | ↗ |
| 2023-08-10 | Watts Ryan J. | Director / Officer | M-Exempt | A | Common Stock | 2,526 | 0.68 | 1.7K | 2,242,439 | — | ↗ |
| 2023-08-10 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,853 | 24.18 | 69.0K | 521,761 | — | ↗ |
| 2023-08-10 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,857 | 24.15 | 69.0K | 185,577 | — | ↗ |
| 2023-07-18 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 9,702 | 30.01 | 291.2K | 518,989 | — | ↗ |
| 2023-07-17 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 10,000 | 29.60 | 296.0K | 528,691 | — | ↗ |
| 2023-07-17 | SATO VICKI L | Director | S-Sale | D | Common Stock | 1,666 | 29.60 | 49.3K | 133,037 | — | ↗ |
| 2023-06-28 | SATO VICKI L | Director | S-Sale | D | Common Stock | 552 | 29.55 | 16.3K | 135,817 | — | ↗ |
| 2023-06-16 | Watts Ryan J. | Director / Officer | M-Exempt | A | Common Stock | 50,000 | 0.68 | 34.0K | 2,289,913 | — | ↗ |
| 2023-06-01 | Thornberry Nancy | Director | A-Award | A | Common Stock | 4,216 | 0.00 | — | 12,713 | — | ↗ |
| 2023-06-01 | Tessier-Lavigne Marc | Director | A-Award | A | Common Stock | 4,216 | 0.00 | — | 1,874,572 | — | ↗ |
| 2023-06-01 | Schenkein David P | Director | A-Award | A | Stock Option (right to buy) | 12,649 | 30.92 | 391.1K | 12,649 | — | ↗ |
| 2023-06-01 | SATO VICKI L | Director | A-Award | A | Common Stock | 4,216 | 0.00 | — | 136,369 | — | ↗ |
| 2023-06-01 | Krognes Steve E. | Director | A-Award | A | Stock Option (right to buy) | 12,649 | 30.92 | 391.1K | 12,649 | — | ↗ |
| 2023-06-01 | Klein Peter S | Director | A-Award | A | Stock Option (right to buy) | 12,649 | 30.92 | 391.1K | 12,649 | — | ↗ |
| 2023-06-01 | Harris Erik | Director | A-Award | A | Stock Option (right to buy) | 12,649 | 30.92 | 391.1K | 12,649 | — | ↗ |
| 2023-06-01 | FLATLEY JAY T | Director | A-Award | A | Stock Option (right to buy) | 12,649 | 30.92 | 391.1K | 12,649 | — | ↗ |
| 2023-06-01 | Cook Jennifer E. | Director | A-Award | A | Stock Option (right to buy) | 12,649 | 30.92 | 391.1K | 12,649 | — | ↗ |
| 2023-06-01 | Cole Douglas G. | Director | A-Award | A | Common Stock | 4,216 | 0.00 | — | 26,564 | — | ↗ |
| 2023-05-15 | Schuth Alexander O. | Officer | M-Exempt | A | Common Stock | 10,000 | 5.28 | 52.8K | 538,691 | — | ↗ |
| 2023-04-21 | Watts Ryan J. | Director / Officer | M-Exempt | A | Common Stock | 24,800 | 0.68 | 16.9K | 2,264,713 | — | ↗ |
| 2023-04-20 | Watts Ryan J. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 200 | 0.68 | 136.00 | 1,195,417 | — | ↗ |
| 2023-04-13 | Schuth Alexander O. | Officer | M-Exempt | D | Stock Option (right to buy) | 4,898 | 5.28 | 25.9K | 88,937 | — | ↗ |
| 2023-04-12 | Schuth Alexander O. | Officer | M-Exempt | A | Common Stock | 5,102 | 5.28 | 26.9K | 533,793 | — | ↗ |
| 2023-02-15 | Ho Carole | Officer | S-Sale | D | Common Stock | 1,476 | 29.40 | 43.4K | 182,809 | — | ↗ |
| 2023-02-13 | Watts Ryan J. | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 0.68 | 17.0K | 2,264,913 | — | ↗ |
| 2023-02-13 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 3,497 | 30.09 | 105.2K | 528,691 | — | ↗ |
| 2023-02-13 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 2,119 | 30.10 | 63.8K | 143,002 | — | ↗ |
| 2023-02-13 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,548 | 30.10 | 76.7K | 184,285 | — | ↗ |
| 2023-02-10 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 25,000 | 29.10 | 727.5K | 2,229,031 | — | ↗ |
| 2023-02-10 | Ho Carole | Officer | S-Sale | D | Common Stock | 818 | 29.80 | 24.4K | 179,365 | — | ↗ |
| 2023-02-09 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 3,433 | 30.59 | 105.0K | 2,229,031 | — | ↗ |
| 2023-02-08 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 1,521 | 30.89 | 47.0K | 499,902 | — | ↗ |
| 2023-02-08 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 1,377 | 30.88 | 42.5K | 145,121 | — | ↗ |
| 2023-02-08 | Ho Carole | Officer | S-Sale | D | Common Stock | 1,521 | 30.88 | 47.0K | 180,183 | — | ↗ |
| 2023-01-17 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 9,886 | 29.53 | 291.9K | 497,287 | — | ↗ |
| 2023-01-09 | Ho Carole | Officer | S-Sale | D | Common Stock | 1,459 | 28.48 | 41.6K | 177,454 | — | ↗ |
| 2023-01-06 | Ho Carole | Officer | S-Sale | D | Common Stock | 1,451 | 28.67 | 41.6K | 178,913 | — | ↗ |
| 2023-01-05 | Watts Ryan J. | Officer | S-Sale | D | Common Stock | 4,800 | 28.44 | 136.5K | 2,223,664 | — | ↗ |
| 2023-01-05 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,636 | 28.44 | 75.0K | 497,173 | — | ↗ |
| 2023-01-05 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 2,970 | 28.44 | 84.5K | 146,498 | — | ↗ |
| 2023-01-05 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,636 | 28.44 | 75.0K | 180,364 | — | ↗ |
| 2023-01-04 | Watts Ryan J. | Officer | S-Sale | D | Common Stock | 5,029 | 28.73 | 144.5K | 2,213,464 | — | ↗ |
| 2023-01-04 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,912 | 28.70 | 83.6K | 149,828 | — | ↗ |
| 2023-01-04 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,913 | 28.69 | 83.6K | 175,500 | — | ↗ |
| 2023-01-03 | Watts Ryan J. | Officer | A-Award | A | Stock Option (right to buy) | 246,720 | 0.00 | — | 246,720 | — | ↗ |
| 2023-01-03 | Schuth Alexander O. | Officer | A-Award | A | Common Stock | 41,120 | 0.00 | — | 157,578 | — | ↗ |
| 2023-01-03 | Ho Carole | Officer | A-Award | A | Common Stock | 41,120 | 0.00 | — | 138,967 | — | ↗ |
| 2022-11-23 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 20,000 | 30.48 | 609.6K | 1,870,356 | — | ↗ |
| 2022-11-02 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 11,252 | 30.33 | 341.3K | 1,890,356 | — | ↗ |
| 2022-11-01 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 8,748 | 30.20 | 264.2K | 1,901,608 | — | ↗ |
| 2022-10-07 | Schuth Alexander O. | Officer | M-Exempt | A | Common Stock | 20,000 | 0.68 | 13.6K | 487,471 | — | ↗ |
| 2022-09-28 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 4,423 | 31.08 | 137.5K | 1,910,356 | — | ↗ |
| 2022-08-23 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 19,900 | 31.61 | 629.0K | 1,930,456 | — | ↗ |
| 2022-08-23 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,424 | 31.98 | 77.5K | 170,663 | — | ↗ |
| 2022-08-19 | Watts Ryan J. | Officer | S-Sale | D | Common Stock | 2,404 | 33.22 | 79.9K | 2,202,993 | — | ↗ |
| 2022-08-19 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,576 | 33.22 | 85.6K | 467,471 | — | ↗ |
| 2022-08-19 | Krognes Steve E. | Director | S-Sale | D | Common Stock | 2,253 | 33.22 | 74.8K | 149,468 | — | ↗ |
| 2022-08-19 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,576 | 33.22 | 85.6K | 173,087 | — | ↗ |
| 2022-08-09 | Schuth Alexander O. | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 121,458 | — | ↗ |
| 2022-08-09 | Ho Carole | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 110,597 | — | ↗ |
| 2022-07-25 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 19,800 | 35.60 | 704.9K | 1,950,556 | — | ↗ |
| 2022-07-19 | Krognes Steve E. | Director | M-Exempt | A | Common Stock | 62,500 | 0.68 | 42.5K | 151,721 | — | ↗ |
| 2022-06-24 | Tessier-Lavigne Marc | Director | D-Return | D | Common Stock | 6,766 | 31.08 | 210.3K | 1,970,356 | — | ↗ |
| 2022-06-23 | Tessier-Lavigne Marc | Director | D-Return | D | Common Stock | 13,250 | 31.10 | 412.1K | 2,017,106 | — | ↗ |
| 2022-06-02 | Thornberry Nancy | Director | A-Award | A | Stock Option (right to buy) | 17,959 | 24.27 | 435.9K | 17,959 | — | ↗ |
| 2022-06-02 | Tessier-Lavigne Marc | Director | A-Award | A | Stock Option (right to buy) | 17,959 | 0.00 | — | 17,959 | — | ↗ |
| 2022-06-02 | Schenkein David P | Director | A-Award | A | Stock Option (right to buy) | 17,959 | 0.00 | — | 17,959 | — | ↗ |
| 2022-06-02 | SATO VICKI L | Director | A-Award | A | Stock Option (right to buy) | 17,959 | 0.00 | — | 17,959 | — | ↗ |
| 2022-06-02 | Klein Peter S | Director | A-Award | A | Common Stock | 5,986 | 0.00 | — | 11,313 | — | ↗ |
| 2022-06-02 | FLATLEY JAY T | Director | A-Award | A | Common Stock | 5,986 | 0.00 | — | 336,313 | — | ↗ |
| 2022-06-02 | Cook Jennifer E. | Director | A-Award | A | Stock Option (right to buy) | 17,959 | 0.00 | — | 17,959 | — | ↗ |
| 2022-06-02 | Cole Douglas G. | Director | A-Award | A | Stock Option (right to buy) | 17,959 | 24.27 | 435.9K | 17,959 | — | ↗ |
| 2022-03-23 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 11,598 | 34.14 | 396.0K | 2,024,370 | — | ↗ |
| 2022-02-11 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 9,491 | 34.72 | 329.5K | 2,129,648 | — | ↗ |
| 2022-02-11 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,803 | 34.68 | 97.2K | 465,047 | — | ↗ |
| 2022-02-11 | Krognes Steve E. | Officer | S-Sale | D | Common Stock | 2,560 | 34.69 | 88.8K | 120,221 | — | ↗ |
| 2022-02-11 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,918 | 34.71 | 101.3K | 170,663 | — | ↗ |
| 2022-02-10 | Watts Ryan J. | Director / Officer | M-Exempt | A | Common Stock | 6,118 | 9.60 | 58.7K | 260,640 | — | ↗ |
| 2022-02-09 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 2,719 | 37.55 | 102.1K | 2,119,442 | — | ↗ |
| 2022-02-09 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 1,423 | 37.10 | 52.8K | 460,564 | — | ↗ |
| 2022-02-09 | Krognes Steve E. | Officer | S-Sale | D | Common Stock | 1,296 | 37.09 | 48.1K | 122,781 | — | ↗ |
| 2022-02-09 | Ho Carole | Officer | S-Sale | D | Common Stock | 1,423 | 37.10 | 52.8K | 166,112 | — | ↗ |
| 2022-02-07 | Harris Erik | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-03 | Harris Erik | Director | A-Award | A | Stock Option (right to buy) | 20,607 | 33.74 | 695.3K | 20,607 | — | ↗ |
| 2022-01-08 | Thornberry Nancy | Director | A-Award | A | Common Stock | 627 | 0.00 | — | 2,511 | — | ↗ |
| 2022-01-05 | Watts Ryan J. | Director / Officer | S-Sale | D | Common Stock | 5,007 | 44.78 | 224.2K | 2,113,361 | — | ↗ |
| 2022-01-05 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,846 | 44.77 | 127.4K | 457,737 | — | ↗ |
| 2022-01-05 | Krognes Steve E. | Officer | S-Sale | D | Common Stock | 2,225 | 44.75 | 99.6K | 124,077 | — | ↗ |
| 2022-01-05 | Ho Carole | Officer | S-Sale | D | Common Stock | 2,845 | 44.78 | 127.4K | 163,285 | — | ↗ |
| 2022-01-03 | Watts Ryan J. | Director / Officer | A-Award | A | Stock Option (right to buy) | 186,500 | 47.27 | 8.82M | 186,500 | — | ↗ |
| 2022-01-03 | Schuth Alexander O. | Officer | A-Award | A | Common Stock | 31,000 | 0.00 | — | 117,454 | — | ↗ |
| 2022-01-03 | Krognes Steve E. | Officer | A-Award | A | Common Stock | 31,000 | 0.00 | — | 126,302 | — | ↗ |
| 2022-01-03 | Ho Carole | Officer | A-Award | A | Common Stock | 31,000 | 0.00 | — | 107,316 | — | ↗ |
| 2021-12-31 | Tessier-Lavigne Marc | Director | — | I | Common Stock | 0 | 0.00 | — | 78,848 | — | ↗ |
| 2021-12-30 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 3,343 | 45.13 | 150.9K | 82,225 | — | ↗ |
| 2021-12-29 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 10,700 | 43.87 | 469.4K | 85,698 | — | ↗ |
| 2021-12-28 | Tessier-Lavigne Marc | Director | S-Sale | D | Common Stock | 3,732 | 44.37 | 165.6K | 96,268 | — | ↗ |
| 2021-12-06 | Schuth Alexander O. | Officer | S-Sale | D | Common Stock | 2,800 | 41.82 | 117.1K | 460,283 | — | ↗ |
Executive team
Top executives
Shares Outstanding
158.71M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 718.0K | 676.7K | 1.15M | 2.18M | — | 24.9K | 4.75M | 70.12% | ↗ |
| 2 | 2025 | Alexander O. Schuth, M.D. Chief Operating and Financial Officer and Secretary | 552.0K | 360.2K | 1.15M | 2.18M | — | 14.0K | 4.26M | 78.25% | ↗ |
| 3 | 2025 | Carole Ho, M.D. Chief Medical Officer and Head of Development (until November 14, 2025) | 483.0K | — | 1.15M | 2.18M | — | 14.0K | 3.83M | 87.02% | ↗ |
| 4 | 2024 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 690.1K | 628.0K | 1.82M | 3.41M | — | 13.8K | 6.56M | 79.69% | ↗ |
| 5 | 2024 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 690.1K | 628.0K | 1.82M | 3.41M | — | 13.8K | 6.56M | 79.69% | ↗ |
| 6 | 2024 | Carole Ho, M.D. Chief Medical Officer | 535.6K | 337.4K | 1.09M | 2.04M | — | 13.8K | 4.02M | 77.96% | ↗ |
| 7 | 2024 | Carole Ho, M.D. Chief Medical Officer and Head of Development (until November 14, 2025) | 535.6K | 337.4K | 1.09M | 2.04M | — | 13.8K | 4.02M | 77.96% | ↗ |
| 8 | 2024 | Alexander O. Schuth, M.D. Chief Operating and Financial Officer and Secretary | 535.6K | 337.4K | 1.09M | 2.04M | — | 13.8K | 4.02M | 77.96% | ↗ |
| 9 | 2024 | Alexander O. Schuth, M.D. Chief Operating and Financial Officer and Secretary | 535.6K | 337.4K | 1.09M | 2.04M | — | 13.8K | 4.02M | 77.96% | ↗ |
| 10 | 2023 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 670.0K | 462.3K | 2.27M | 4.46M | — | 13.2K | 7.88M | 85.46% | ↗ |
| 11 | 2023 | Carole Ho, M.D. Chief Medical Officer | 520.0K | 269.1K | 1.14M | 2.23M | — | 13.2K | 4.17M | 80.76% | ↗ |
| 12 | 2023 | Alexander O. Schuth, M.D. Chief Operating and Financial Officer and Secretary | 520.0K | 269.1K | 1.14M | 2.23M | — | 13.2K | 4.17M | 80.76% | ↗ |
| 13 | 2022 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 645.0K | 387.0K | 2.93M | 5.31M | — | 12.2K | 9.28M | 88.75% | ↗ |
| 14 | 2022 | Alexander O. Schuth, M.D. Chief Operating and Financial Officer and Secretary | 500.0K | 225.0K | 2.31M | 2.65M | — | 12.2K | 5.69M | 87.05% | ↗ |
| 15 | 2022 | Carole Ho, M.D. Chief Medical Officer | 500.0K | 225.0K | 2.31M | 2.65M | — | 12.2K | 5.69M | 87.05% | ↗ |
| 16 | 2022 | Steve E. Krognes Chief Financial Officer and Treasurer (until May 1, 2022) | 167.1K | — | 1.47M | 2.65M | — | 6.7K | 4.29M | 95.95% | ↗ |
| 17 | 2021 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 610.1K | 503.3K | 4.25M | 7.30M | — | 11.6K | 12.67M | 91.12% | ↗ |
| 18 | 2021 | Steve E. Krognes Chief Financial Officer and Treasurer (until May 1, 2022) | 501.2K | 300.7K | 2.13M | 3.65M | — | 11.6K | 6.59M | 87.65% | ↗ |
| 19 | 2021 | Steve E. Krognes Chief Financial Officer and Treasurer | 501.2K | 300.7K | 2.13M | 3.65M | — | 11.6K | 6.59M | 87.65% | ↗ |
| 20 | 2021 | Carole Ho, M.D. Chief Medical Officer | 473.6K | 284.2K | 2.13M | 3.65M | — | 11.6K | 6.54M | 88.24% | ↗ |
| 21 | 2021 | Alexander O. Schuth, M.D. Chief Operating Officer and Secretary | 465.1K | 279.1K | 2.13M | 3.65M | — | 11.6K | 6.53M | 88.43% | ↗ |
| 22 | 2021 | Alexander O. Schuth, M.D. Chief Operating and Financial Officer and Secretary | 465.1K | 279.1K | 2.13M | 3.65M | — | 11.6K | 6.53M | 88.43% | ↗ |
| 23 | 2020 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 589.5K | 648.4K | 2.60M | 5.46M | — | 11.4K | 9.30M | 86.57% | ↗ |
| 24 | 2020 | Carole Ho, M.D. Chief Medical Officer | 457.6K | 366.1K | 1.38M | 2.11M | — | 11.4K | 4.33M | 80.69% | ↗ |
| 25 | 2020 | Steve E. Krognes Chief Financial Officer and Treasurer | 484.2K | 387.4K | 1.36M | 2.02M | — | 11.4K | 4.27M | 79.30% | ↗ |
| 26 | 2020 | Steve E. Krognes Chief Financial Officer and Treasurer (until May 1, 2022) | 484.2K | 387.4K | 1.36M | 2.02M | — | 11.4K | 4.27M | 79.30% | ↗ |
| 27 | 2020 | Alexander O. Schuth, M.D. Chief Operating and Financial Officer and Secretary | 449.4K | 359.5K | 1.36M | 2.02M | — | 11.4K | 4.20M | 80.48% | ↗ |
| 28 | 2020 | Alexander O. Schuth, M.D. Chief Operating Officer and Secretary | 449.4K | 359.5K | 1.36M | 2.02M | — | 11.4K | 4.20M | 80.48% | ↗ |
| 29 | 2019 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 566.8K | 311.7K | 838.2K | 3.25M | — | 9.4K | 4.98M | 82.16% | ↗ |
| 30 | 2019 | Steve E. Krognes Chief Financial Officer and Treasurer | 470.1K | 188.0K | 305.8K | 1.56M | — | 7.8K | 2.53M | 73.69% | ↗ |
| 31 | 2019 | Carole Ho, M.D. Chief Medical Officer | 440.0K | 176.0K | 305.8K | 1.56M | — | 8.8K | 2.49M | 74.90% | ↗ |
| 32 | 2019 | Alexander O. Schuth, M.D. Chief Operating Officer and Secretary | 428.0K | 171.2K | 305.8K | 1.56M | — | 12.7K | 2.48M | 75.29% | ↗ |
| 33 | 2018 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 545.0K | 524.6K | — | 4.91M | — | — | 5.98M | 82.13% | ↗ |
| 34 | 2018 | Steve E. Krognes Chief Financial Officer and Treasurer | 455.3K | 393.7K | 179.7K | 2.95M | — | 24.0K | 4.00M | 78.18% | ↗ |
| 35 | 2018 | Carole Ho, M.D. Chief Medical Officer | 423.1K | 371.2K | 179.7K | 2.95M | — | 12.9K | 3.94M | 79.49% | ↗ |
| 36 | 2018 | Alexander O. Schuth, M.D. Chief Operating Officer and Secretary | 400.0K | 355.0K | 179.7K | 2.95M | — | 18.5K | 3.90M | 80.18% | ↗ |
| 37 | 2017 | Carole Ho, M.D. Chief Medical Officer | 406.9K | 203.4K | — | 746.0K | — | 11.7K | 1.37M | 54.53% | ↗ |
| 38 | 2017 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 481.1K | 374.7K | — | 497.4K | — | 13.8K | 1.37M | 36.39% | ↗ |
| 39 | 2017 | Steve E. Krognes Chief Financial Officer and Treasurer | 437.8K | 218.9K | — | 497.4K | — | 12.6K | 1.17M | 42.63% | ↗ |
| 40 | 2017 | Alexander O. Schuth, M.D. Chief Operating Officer and Secretary | 369.0K | 200.0K | — | 497.4K | — | 10.6K | 1.08M | 46.18% | ↗ |
| 41 | 2016 | Carole Ho, M.D. Chief Medical Officer | 395.0K | 138.3K | — | 495.6K | — | — | 1.03M | 48.17% | ↗ |
| 42 | 2016 | Steve E. Krognes Chief Financial Officer and Treasurer | 425.0K | 398.8K | — | — | — | — | 823.8K | 0.00% | ↗ |
| 43 | 2016 | Ryan J. Watts, Ph.D. President and Chief Executive Officer | 450.0K | 157.5K | — | — | — | — | 607.5K | 0.00% | ↗ |
| 44 | 2016 | Alexander O. Schuth, M.D. Chief Operating Officer and Secretary | 350.0K | 122.5K | — | — | — | — | 472.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ryan J. Watts | Co-Founder, President, Chief Executive Officer & Director | 1M | — |
| Alexander O. Schuth | Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary | 926.2K | — |
| Cindy Dunkle | Chief People Officer | — | female |
| Dana Andersen | Chief Technical and Manufacturing Officer | — | — |
| Joe Lewcock | Chief Scientific Officer | — | male |
| Katie Peng | Chief Commercial Officer | — | female |
| Peter Chin | Acting Chief Medical Officer & Head of Development | — | male |
| Chris Walsh | General Counsel | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DNLI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
